Literature DB >> 20231369

MIB-1 labeling index correlated with magnetic resonance imaging detected tumor volume doubling time in pituitary adenoma.

Chih-Yi Hsu1, Wan-Yuo Guo, Chen-Ping Chien, Donald Ming-Tak Ho.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate whether MIB-1 labeling index (LI) could be used to predict growth velocity of residual pituitary adenomas after surgery.
MATERIALS AND METHODS: One hundred and sixty pituitary adenomas which had not received other treatment modality except for surgery were collected. Each of them had at least two post-operative magnetic resonance imaging (MRI) studies with an interval of at least 1 month apart. Tumor volume doubling time (TVDT) was calculated for those in which volume increased.
RESULTS: Post-operative tumor progression was noted in 54 (33.8%) cases, of which 39 (72.2%) cases were non-functioning adenomas. The MIB-1 LIs of the functioning and non-functioning adenomas were not significantly different. The median TVDT of these 54 cases was 34.6 months. The mean and median MIB-1 LI were 2.7 and 1.1 respectively (range 0.4-20.6). The MIB-1 LI was significantly correlated with log(2)(TVDT) (r=-0.363, P=0.007); when LI was <0.8, the TVDT of 90.5% cases was >or= 2 years.
CONCLUSIONS: Only one-third of the pituitary adenomas progressed after surgery, and their MIB-1 LIs were generally low. The MIB-1 LI was significantly correlated with the MRI detected TVDT of post-operative residual pituitary adenomas.

Entities:  

Mesh:

Year:  2010        PMID: 20231369     DOI: 10.1530/EJE-09-1100

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.

Authors:  Liang Lv; Yong Jiang; Senlin Yin; Yu Hu; Cheng Chen; Weichao Ma; Shu Jiang; Peizhi Zhou
Journal:  Endocrine       Date:  2019-07-31       Impact factor: 3.633

Review 2.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

3.  Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Authors:  Kristin Astrid Øystese; Manuela Zucknick; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2017-05-17       Impact factor: 3.633

4.  Clinical features, surgical management, and long-term prognosis of intraventricular meningiomas: A large series of 89 patients at a single institution.

Authors:  Cheng Chen; Liang Lv; Yu Hu; Senlin Yin; Peizhi Zhou; Shu Jiang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

5.  Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

Authors:  Christian P Miermeister; Stephan Petersenn; Michael Buchfelder; Rudolf Fahlbusch; Dieter K Lüdecke; Annett Hölsken; Markus Bergmann; Hans Ulrich Knappe; Volkmar H Hans; Jörg Flitsch; Wolfgang Saeger; Rolf Buslei
Journal:  Acta Neuropathol Commun       Date:  2015-08-19       Impact factor: 7.801

6.  MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

Authors:  Alexander S G Micko; Adelheid Wöhrer; Romana Höftberger; Greisa Vila; Christine Marosi; Engelbert Knosp; Stefan Wolfsberger
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

7.  Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study.

Authors:  Liang Lyu; Senlin Yin; Yu Hu; Cheng Chen; Yong Jiang; Yang Yu; Weichao Ma; Zeming Wang; Shu Jiang; Peizhi Zhou
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.